Every day, our field-proven, AI-powered diagnostic solutions help pathologists ensure better cancer care for thousands of patients.


Created by pathologists for pathologists


Delivering real-world clinical impact


The worldwide leader in live clinical rollouts


Platform of choice for the world’s leading physicians, health systems and diagnostic solution providers

Ibex Partners with AstraZeneca and Daiichi Sankyo

The companies will validate and bring to market Ibex’s AI-powered biomarker scoring product, allowing pathologists to optimize breast cancer diagnosis and help select patients eligible for HER2-directed therapy.

Read More

The Ibex Difference

  • AI-powered solutions detect cancer and hundreds of other cellular features in multiple tissue types
  • Clinically-proven accuracy, enhanced efficiency and improved user experience
  • Developed from a dataset of over 10 million slides from multiple pathology institutes, reinforced with millions of pathology reports and medical records spanning decades of patient data
  • AI algorithms trained by teams of expert pathologists using deep learning technologies
Trusted AI

Why Ibex


Accurate, timely, personalized cancer diagnosis for every patient


Higher quality,
more targeted,
high-impact care


Enhanced physician confidence and patient safety


Faster diagnosis, better user experience and lower pathology workloads


Optimized workflows improve productivity across the cancer pathway

Our Partners

The role of AI in pathology and how it impacts cancer care

Prof. Stuart Schnitt from Brigham and Women's Hospital talks about Galen Breast and how its accuracy and broad detection capabilities transform pathologists' work

Watch video

Experience the future of pathology

Contact Us

    By providing my details I agree to the IBEX Terms and conditions and Privacy policy. I also agree to receive emails from IBEX and I understand that I may opt out of IBEX subscriptions at any time.